ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
H2 수용체 길항제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 5.5%의 CAGR로 53억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 생활습관 관련 소화기 질환 사례 증가, 비처방 위장약에 대한 수요 증가, 만성 산성 문제를 가진 노인 인구의 증가, 제네릭 제제의 가용성 확대, 소아 친화적 제제 개발 등입니다. 예측 기간 동안 예상되는 주요 동향으로는 서방형 제제 개발, 디지털 건강 모니터링 도구와의 통합, 소아 제형 혁신, 프로바이오틱스와의 병용요법, 고온 기후에 대응하는 화합물 안정성 개발 등이 있습니다.
H2 수용체 길항제 시장의 성장을 견인할 것으로 예상되는 것은 위장 질환의 유병률 증가입니다. 위장관 질환은 감염, 염증, 위나 장의 장애 등 소화관에 영향을 미치는 질환을 말합니다. 위장 질환의 증가는 건강에 해로운 식습관과 가공식품의 소비 증가에 기인하며, 이는 장 건강을 방해하고 위산 역류, 과민성대장증후군(IBS), 궤양과 같은 소화기 질환을 유발할 수 있습니다. 역류, 궤양, 위염 등의 증상을 완화하여 이러한 증상을 해결합니다. 예를 들어, 2023년 1월 미국암협회(ACS)는 미국 내 소화기암 환자 수가 3.18% 증가하여 2022년 338,090명에서 2023년 348,840명으로 증가할 것이라고 보고했습니다. 이에 따라 소화기 질환의 발병률 증가가 H2 수용체 길항제 시장 확대를 견인하고 있습니다.
H2 수용체 길항제 시장의 기업들은 산 억제 치료의 효과, 편의성, 환자 순응도를 향상시키기 위해 새로운 약물전달 시스템과 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 새로운 약물전달 시스템은 치료제를 제어된 표적에 따라 지속적으로 방출하여 효능을 높이고 환자의 복약 순응도를 향상시키도록 설계된 첨단 기술입니다. 예를 들어, 2022년 6월 인도 제약사 자이더스 라이프사이언스는 GERD 등 산 관련 질환 치료용 구강붕해정인 파모티딘 ODT를 출시했습니다. 이 제제는 특히 삼키기 어려운 환자도 물 없이 복용할 수 있어 편의성과 순응도를 높인 것이 특징입니다. 자이더스는 이 혁신이 약물의 사용 편의성을 높이고 더 빠른 완화를 통해 더 나은 치료 결과를 얻을 수 있다고 강조하고 있습니다. 이러한 전달 시스템의 채택은 환자의 치료 경험과 접근성을 향상시킴으로써 H2 수용체 길항제 시장의 성장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 H2 수용체 길항제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 H2 수용체 길항제 시장 : 성장률 분석
세계의 H2 수용체 길항제 시장 실적 : 규모와 성장, 2019-2024년
세계의 H2 수용체 길항제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 H2 수용체 길항제 전체 시장(TAM)
제6장 시장 세분화
세계의 H2 수용체 길항제 시장 : 약물 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Cimetidine
Ranitidine
Famotidine
Nizatidine
세계의 H2 수용체 길항제 시장 : 적응증별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
위식도역류질환(GERD)
소화성궤양
졸링거-엘리슨 증후군
기타 적응증
세계의 H2 수용체 길항제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
정맥내
근육내
세계의 H2 수용체 길항제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 H2 수용체 길항제 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
클리닉
재택 케어 설정
제7장 지역별·국가별 분석
세계의 H2 수용체 길항제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 H2 수용체 길항제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
H2 수용체 길항제 시장 : 경쟁 구도
H2 수용체 길항제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Viatris Inc.
Teva Pharmaceutical Industries Limited
Boehringer Ingelheim International GmbH
Sun Pharmaceutical Industries Limited
Apotex Inc.
Aurobindo Pharma Limited
Dr. Reddy's Laboratories Limited
Cipla Limited
Hikma Pharmaceuticals plc
Lupin Ltd.
Zydus Lifesciences Limited
Torrent Pharmaceuticals Limited
Accord Healthcare Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
H2 수용체 길항제 시장 2029년 : 새로운 기회를 제공하는 국가
H2 수용체 길항제 시장 2029년 : 새로운 기회를 제공하는 부문
H2 수용체 길항제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
H2 receptor antagonists are a class of medications that block histamine receptors in the stomach, reducing acid production to treat conditions such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). These drugs work by inhibiting the H2 receptors on parietal cells in the stomach lining, which are responsible for secreting gastric acid.
The main drug classes of H2 receptor antagonists include cimetidine, ranitidine, famotidine, and nizatidine. Cimetidine is an H2 receptor antagonist that reduces stomach acid production by blocking histamine H2 receptors on the gastric parietal cells. These drugs are indicated for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, and others. They are administered through various routes, including oral, intravenous, and intramuscular. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others. The primary end users include hospitals, clinics, and home care settings.
The H2 receptor antagonist market research report is one of a series of new reports from The Business Research Company that provides H2 receptor antagonist market statistics, including the H2 receptor antagonist industry global market size, regional shares, competitors with the H2 receptor antagonist market share, detailed H2 receptor antagonist market segments, market trends, and opportunities, and any further data you may need to thrive in the H2 receptor antagonist industry. This H2 receptor antagonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The H2 receptor antagonist market size has grown strongly in recent years. It will grow from $4.08 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of peptic ulcers, widespread use of over-the-counter antacids, increasing diagnoses of gastroesophageal reflux disease (GERD), strong adoption in hospital settings, and a rising incidence of gastrointestinal disorders.
The H2 receptor antagonist market size is expected to see strong growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period is driven by rising cases of lifestyle-related digestive disorders, increasing demand for non-prescription gastrointestinal treatments, a growing geriatric population with chronic acid issues, expanding availability of generic formulations, and the development of pediatric-friendly formulations. Key trends expected in the forecast period include the development of extended-release formulations, integration with digital health monitoring tools, innovation in pediatric dosage forms, combination therapies with probiotics, and advances in compound stability for hot climates.
The increasing incidence of gastrointestinal diseases is expected to drive the growth of the H2 receptor antagonist market. Gastrointestinal diseases are conditions that affect the digestive tract, including infections, inflammation, and disorders of the stomach and intestines. The rise in gastrointestinal diseases is largely attributed to unhealthy dietary habits and the increasing consumption of processed foods, which can disrupt gut health and lead to digestive disorders such as acid reflux, irritable bowel syndrome (IBS), and ulcers. H2 receptor antagonists address these conditions by blocking histamine receptors in the stomach, reducing acid production, and alleviating symptoms such as acid reflux, ulcers, and gastritis. For example, in January 2023, the American Cancer Society (ACS) reported a 3.18% increase in gastrointestinal cancer cases in the United States, rising from 338,090 in 2022 to 348,840 in 2023. As a result, the growing incidence of gastrointestinal diseases is driving the expansion of the H2 receptor antagonist market.
Companies in the H2 receptor antagonist market are focusing on developing innovative solutions, such as novel drug delivery systems, to improve the efficacy, convenience, and patient compliance of acid-suppressing treatments. Novel drug delivery systems are advanced technologies designed to release therapeutic agents in a controlled, targeted, and sustained manner for enhanced efficacy and better patient adherence. For instance, in June 2022, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Famotidine ODT, an orally disintegrating tablet for treating acid-related disorders such as GERD. This formulation allows patients, especially those with difficulty swallowing, to take the medication without water, improving convenience and compliance. Zydus highlighted that this innovation supports better treatment outcomes by making the medication easier to use and providing faster relief. The adoption of such delivery systems is helping to drive growth in the H2 receptor antagonist market by enhancing the therapeutic experience and accessibility for patients.
In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen's position in rare diseases and immunology by expanding its portfolio with Horizon's innovative therapies and global commercial capabilities. Horizon Therapeutics, an Ireland-based company, manufactures H2 receptor antagonists, enhancing Amgen's footprint in the gastrointestinal and inflammation treatment market.
Major players in the h2 receptor antagonist market are Pfizer Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Apotex Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Lupin Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Accord Healthcare Limited.
North America was the largest region in the H2 receptor antagonist market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in H2 receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the H2 receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The H2 receptor antagonist market consists of sales of tegoprazan and lansoprazole. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
H2 Receptor Antagonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on h2 receptor antagonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for h2 receptor antagonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h2 receptor antagonist market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Cimetidine; Ranitidine; Famotidine; Nizatidine
2) By Route of Administration: Oral; Intravenous; Intramuscular
3) By Indication: Gastroesophageal Reflux Disease (GERD); Peptic Ulcers; Zollinger-Ellison Syndrome; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
5) By End-User: Hospitals; Clinics; Home Care Settings
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. H2 Receptor Antagonist Market Characteristics
3. H2 Receptor Antagonist Market Trends And Strategies
4. H2 Receptor Antagonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global H2 Receptor Antagonist Growth Analysis And Strategic Analysis Framework
5.1. Global H2 Receptor Antagonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global H2 Receptor Antagonist Market Growth Rate Analysis
5.4. Global H2 Receptor Antagonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global H2 Receptor Antagonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global H2 Receptor Antagonist Total Addressable Market (TAM)
6. H2 Receptor Antagonist Market Segmentation
6.1. Global H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cimetidine
Ranitidine
Famotidine
Nizatidine
6.2. Global H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastroesophageal Reflux Disease (GERD)
Peptic Ulcers
Zollinger-Ellison Syndrome
Other Indications
6.3. Global H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Intramuscular
6.4. Global H2 Receptor Antagonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.5. Global H2 Receptor Antagonist Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Care Settings
7. H2 Receptor Antagonist Market Regional And Country Analysis
7.1. Global H2 Receptor Antagonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global H2 Receptor Antagonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China H2 Receptor Antagonist Market
9.1. China H2 Receptor Antagonist Market Overview
9.2. China H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India H2 Receptor Antagonist Market
10.1. India H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan H2 Receptor Antagonist Market
11.1. Japan H2 Receptor Antagonist Market Overview
11.2. Japan H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia H2 Receptor Antagonist Market
12.1. Australia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia H2 Receptor Antagonist Market
13.1. Indonesia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea H2 Receptor Antagonist Market
14.1. South Korea H2 Receptor Antagonist Market Overview
14.2. South Korea H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe H2 Receptor Antagonist Market
15.1. Western Europe H2 Receptor Antagonist Market Overview
15.2. Western Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK H2 Receptor Antagonist Market
16.1. UK H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany H2 Receptor Antagonist Market
17.1. Germany H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France H2 Receptor Antagonist Market
18.1. France H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy H2 Receptor Antagonist Market
19.1. Italy H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain H2 Receptor Antagonist Market
20.1. Spain H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe H2 Receptor Antagonist Market
21.1. Eastern Europe H2 Receptor Antagonist Market Overview
21.2. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia H2 Receptor Antagonist Market
22.1. Russia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America H2 Receptor Antagonist Market
23.1. North America H2 Receptor Antagonist Market Overview
23.2. North America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA H2 Receptor Antagonist Market
24.1. USA H2 Receptor Antagonist Market Overview
24.2. USA H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America H2 Receptor Antagonist Market
26.1. South America H2 Receptor Antagonist Market Overview
26.2. South America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil H2 Receptor Antagonist Market
27.1. Brazil H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East H2 Receptor Antagonist Market
28.1. Middle East H2 Receptor Antagonist Market Overview
28.2. Middle East H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa H2 Receptor Antagonist Market
29.1. Africa H2 Receptor Antagonist Market Overview
29.2. Africa H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. H2 Receptor Antagonist Market Competitive Landscape And Company Profiles
